dihexa clinical trials human humans Sublingual BPC-157 dihexa clinical trials status Dihexa
Description
Even if compounding becomes permissible, promotional rules still apply
The AOD-9604 OPTIONS study: 536 subjects, 24 weeks, and a failed primary endpoint The Phase 2b OPTIONS Study enrolled 536 subjects and ran for 24 weeks, measuring weight loss and body fat reduction as primary and secondary endpoints
Gut Health and Digestive Support Since the BPC-157 peptide comes from a stomach protein, it naturally helps the digestive system
7 Tips for your OA Patients
